De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trialXiuchun Chen, Zhenzhen Liu, Lianfang Li et al.|The Lancet Oncology|2024Cited by 32
Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trialMin Yan, Huajun Li, Limin Niu et al.|Nature Communications|2023Cited by 14
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trialMin Yan, Fangzhou Xia, Quchang Ouyang et al.|EClinicalMedicine|2024Cited by 10